Search
Protein S100-A12
go.drugbank.com/bio_entities/BE0001206TargetHumansS100A12 is a calcium-, zinc- and copper-binding protein which plays a prominent role in the regulation of inflammatory processes and immune response.
Synonyms: Calcium-binding protein in amniotic fluid 1Octocrylene
go.drugbank.com/drugs/DB09535ApprovedOctocrylene is a compound often used as an additive in sun screen, and is thought to have skin moisturizing effects because of its emollient properties. … Because of its effectiveness, the chemical has been approved across the globe for use in cosmetics and skin care products, but the concentrations of this ingredient are usually limited to no more than
Mixtures: Bullet Line, Bullet LineBrain Metastases
go.drugbank.com/conditions/DBCOND0029546Synonyms: Metastatic Malignant Neoplasm in the BrainAIDS-related Kaposi's Sarcoma
go.drugbank.com/conditions/DBCOND0025353Synonyms: HIV disease resulting in Kaposi's sarcoma (disorder)Erdafitinib
go.drugbank.com/drugs/DB12147ApprovedInvestigational[L5956, L5959] Considering urothelial cancer is statistically the fourth most common kind of cancer in the world, the introduction of erdafitinib offers a much-needed new option in the ever-expanding therapeutic … In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for
Candesartan cilexetil
go.drugbank.com/drugs/DB00796ApprovedInvestigationalIt is administered orally as the prodrug, candesartan cilexetil, which is rapidly converted to its active metabolite, candesartan, during absorption in the gastrointestinal tract. … Candesartan is an angiotensin-receptor blocker (ARB) that may be used alone or with other agents to treat hypertension.
Categories: Angiotensin II receptor antagonists, Angiotensin II Antagonists and DiureticsCiltacabtagene autoleucel
go.drugbank.com/drugs/DB16738ApprovedInvestigational[A245854] While normally expressed on plasma blasts and plasma cells, BCMA is widely expressed on malignant plasma cells and most multiple myeloma cell lines, making it a choice target in the development … [A245854] Carvykti was first approved by the FDA in February 2022 for the treatment of relapsed or refractory multiple myeloma in treatment-experienced patients.[L40744]
Riboflavin
go.drugbank.com/drugs/DB00140ApprovedInvestigationalNutraceuticalVet approvedIt occurs in the free form only in the retina of the eye, in whey, and in urine; its principal forms in tissues and cells are as flavin mononucleotide and flavin-adenine dinucleotide. … Nutritional factor found in milk, eggs, malted barley, liver, kidney, heart, and leafy vegetables. The richest natural source is yeast.
Mixtures: Multi II IV Vi Tab, Vc IIDaxibotulinumtoxinA
go.drugbank.com/drugs/DB17929ApprovedInvestigational[A261075, L47860] DaxibotulinumtoxinA was first approved by the FDA on September 8, 2022, for the temporary improvement of glabellar lines. … _C. botulinum_ is known to produce toxins that can cause botulism in humans.
Necitumumab
go.drugbank.com/drugs/DB09559ApprovedInvestigationalWithdrawnNecitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). … Necitumumab is an intravenously administered recombinant monoclonal IgG1 antibody used in the treatment of non-small cell lung cancer (NSCLC) as an EGFR antagonist.